Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciltacabtagene Autoleucel in Newly Diagnosed Multiple Myeloma
NCT07149857Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2025
- Primary completion
- Apr 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 3
01
Overview
Phase 2, open-label trial of ciltacabtagene autoleucel in multiple myeloma (MM) (2 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoint: Minimal Residual Disease-negative Complete Response After Cilta-cel Infusion at 12 months. Started Oct 2025; status: recruiting.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07149857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07149857.